Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.

By L. Hofbauer, M. Schoppet. Journal of the American Medical Association (JAMA), 2004

1,014 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Inflammatory and immune pathways in the pathogenesis of periodontal disease (2014, background): “osteoporosis, cancer-related bone metastasis and diabetes-associated alveolar bone destruction (25, 87, 89, 122, 158, 169), confirming the critical role of the RANKL ⁄ RANK ⁄ osteoprotegerin triad in osteoclas-”
Biology of RANK, RANKL, and osteoprotegerin (2007, background): “Many reports have supported the assertion that the RANKL/OPG ratio is a major determinant of bone mass [28].”
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets (2007, background): “RANKL binds to RANK on osteoclasts, thereby stimulating their differentiation and activity, whereas OPG functions as a decoy receptor by binding to RANKL and preventing its interaction with RANK, thereby inhibiting its ability to stimulate osteoclastogenesi”